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Abstract
Worm-like and spherical micelles are both prepared here from the same amphiphilic diblock copolymer,
poly(ethylene oxide)-b-poly (ε-caprolactone) (PEO [5 kDa]-PCL [6.5 kDa]) in order to compare loading and
delivery of hydrophobic drugs. Worm-like micelles of this degradable copolymer are nanometers in cross-
section and spontaneously assemble to stable lengths of microns, resembling filoviruses in some respects and
thus suggesting the moniker "filomicelles". The highly flexible worm-like micelles can also be sonicated to
generate kinetically stable spherical micelles composed of the same copolymer. The fission process exploits
the finding that the PCL cores are fluid, rather than glassy or crystalline, and core-loading of the hydrophobic
anticancer drug delivery, paclitaxel (TAX) shows that the worm-like micelles load and solubilize twice as
much drug as spherical micelles. In cytotoxicity tests that compare to the clinically prevalent solubilizer,
Cremophor® EL, both micellar carriers are far less toxic, and both types of TAX-loaded micelles also show
5-fold greater anticancer activity on A549 human lung cancer cells. PEO-PCL based worm-like filomicelles
appear to be promising pharmaceutical nanocarriers with improved solubilization efficiency and comparable
stability to spherical micelles, as well as better safety and efficacy in vitro compared to the prevalent
Cremophor® EL TAX formulation.
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2 Micelles of Different Morphologies—Advantages of Worm-like Filomicelles
3 of PEO-PCL in Paclitaxel Delivery
4 Shenshen Cai,1 Kandaswamy Vijayan,1 Debbie Cheng,1 Eliana M. Lima,1 and Dennis E. Discher1,2
5 Received April 10, 2007; accepted May 2, 2007
6 Abstract. Worm-like and spherical micelles are both prepared here from the same amphiphilic diblock
7 copolymer, poly(ethylene oxide)-b-poly ((-caprolactone) (PEO [5 kDa]-PCL [6.5 kDa]) in order to
8 compare loading and delivery of hydrophobic drugs. Worm-like micelles of this degradable copolymer
9 are nanometers in cross-section and spontaneously assemble to stable lengths of microns, resembling
10 filoviruses in some respects and thus suggesting the moniker Ffilomicelles_. The highly flexible worm-like
11 micelles can also be sonicated to generate kinetically stable spherical micelles composed of the same
12 copolymer. The fission process exploits the finding that the PCL cores are fluid, rather than glassy or
13 crystalline, and core-loading of the hydrophobic anticancer drug delivery, paclitaxel (TAX) shows that
14 the worm-like micelles load and solubilize twice as much drug as spherical micelles. In cytotoxicity tests
15 that compare to the clinically prevalent solubilizer, Cremophor\ EL, both micellar carriers are far less
16 toxic, and both types of TAX-loaded micelles also show 5-fold greater anticancer activity on A549
17 human lung cancer cells. PEO-PCL based worm-like filomicelles appear to be promising pharmaceutical
18 nanocarriers with improved solubilization efficiency and comparable stability to spherical micelles, as
19 well as better safety and efficacy in vitro compared to the prevalent Cremophor\ EL TAX formulation.
21 KEY WORDS: lung carcinoma cells; paclitaxel; poly((-caprolactone); poly(ethylene oxide);
22 worm-like micelle.
24 INTRODUCTION
25 Parenteral delivery of chemotherapeutics is a cornerstone
26 of clinical cancer treatment, but many drugs are hydrophobic
27 and require a solubilizing carrier. Such systems must load and
28 stably retain anticancer drugs and must also have a means to
29 release drugs into cells. Anticancer drug delivery systems have
30 thus far included bioconjugates (1–3), nanoparticles (4,5),
31 liposomes (6,7), polymersomes (8–10), and polymeric micelles
32 composed of amphiphilic block copolymers (11,12), but all of
33 the cited carriers are essentially spherical in shape. Long and
34 flexible Bworm-like^ micelle carriers made from amphiphilic
35 block copolymers are described here in terms of formulation
36 and in vitro delivery, and the findings follow up on recent
37 studies that demonstrate surprisingly persistent circulation and
38 potent anti-tumor activity of worm-like micelles in vivo (13).
39 Paclitaxel (TAX) is a clinically prevalent anticancer agent
40 used against a variety of solid tumors (14–17), and it works by
41 stabilizing microtubules and inhibiting cytoskeleton-mediated
42 processes such as mitosis (18). However, the extremely low
43 water solubility of TAX at 0.3 mg/ml (25-C) (18) or 3–4 mg/ml
44 at 37-C (19) has motivated both covalent modifications to
45 increase solubility (20) as well as loading into various types of
46 carrier systems. As the most common emulsifying agent used
47in the clinic to solubilize TAX, Cremophor\ EL is a complex,
48viscous mixture composed primarily of hydrophobic glycer-
49olpolyoxyethylene ricinoleates, various fatty acid esters, and
50õ50% ethanol (21,22), but clinical problems associated with
51Cremophor EL include low drug stability after dilution in
52aqueous medium (23) and severe, dose-limiting side effects
53such as hypersensitivity and cardiotoxicity (20,24,25). There is
54therefore a need for safer and more effective TAX delivery
55systems.
56Amphiphilic diblock copolymers generally self-assemble
57in dilute aqueous solution into three basic morphologies:
58spherical micelles, worm-like micelles, and vesicles. Spherical
59micelles form spontaneously when the hydrophilic, corona
60block such as poly(ethylene oxide) (PEO) is the largest block
61by mass, and these have now been widely studied in bio-
62application. Following parental administration, such spheres
63delay clearance by macrophages of the liver and spleen due
64to the hydrated corona and also—it has been thought—due
65to their small size (26). Escape from clearance in principle
66allows accumulation in tumors, and use of copolymers that
67are degradable (27,28) or sensitive to temperature or pH can
68provide mechanisms for controlled drug release (18,24,29).
69By decreasing the weight fraction of the PEO block to just
70less than õ50%, hydration and swelling of the corona imparts
71just enough curvature to the copolymer assembly that worm-
72like micelles that are microns in length and similar in
73diameter to the spheres are the predominant morphology
74for a variety of diblock copolymers (30,31). Drugs such as
75TAX and various hydrophobic dyes have now been loaded
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76 into these novel carriers (30,32–34), and worm-like micelles
77 in vivro persist for up to 1 week in the blood circulation,
78 which appears longer than any other synthetic particle,
79 including stealthy vesicles bearing the same length of PEO
80 chains (13). In some sense, the worm-like micelles are bio-
81 inspired by filoviruses that can also circulate and infect
82 human cells, which is why the micelles are hereafter referred
83 to as filomicelles.
84 In this study, worm-like filomicelles and spherical
85 micelles were both prepared from the same poly (ethylene
86 oxide)-b-poly ((-caprolactone) (PEO-PCL, denoted OCL) as
87sketched in Fig. 1a. Drug loading capacities were then
88directly compared, and show that approximately 2-fold
89higher TAX loading is possible with worm-like filomicelles.
90For both systems, TAX release is similarly enhanced at lower
91pH, which is favorable as cancerous tissues are generally
92associated with acidic environment (29,35). Compared to
93Cremophor EL, both polymeric micelle carriers show signif-
94icantly less cytotoxicity and greater potency in delivering
95TAX to human lung carcinoma A549 cells. OCL-based
96worm-like filomicelles thus appear to be a promising new
97system for drug delivery.
b
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Fig. 1. Preparation of OCL3 polymeric micelles. a Scheme of making OCL3 micelles in worm-like and spherical morphologies; b visualization
of worm-like micelles under fluorescence microscopy (left) and the contour length distribution of worm-like micelles, inset showing an
enlarged worm-like micelle (right). Scale bar 5 mm
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98 MATERIALS AND METHODS
99 Materials
100 Diblock polymer poly (ethylene oxide)-b-poly ((-caprolactone)
101 (Mn =5,000–6,500, weight fraction of PEO fEO=0.43, polydispersity=
102 1.3, denoted OCL3) was purchased from Polymersource
103 (Dorval, Canada). Paclitaxel (TAX), docetaxel, Cremophor
104 EL, fluorescent PKH26 dye, Dulbecco_s phosphate-buffered
105 saline (DPBS) and methylthiazolyldiphenyl-tetrazolium
106 bromide (MTT) were from Sigma (St. Louis, MO). Human
107 lung carcinoma cells A549 were obtained from ATCC
108 (Manassas, VA). F12 Ham media was purchased from
109 Mediatech (Herndon, VA). All organic solvents were
110 analytical grade from Fisher Scientific.
111 Preparation of OCL3 Polymeric Micelles by Cosolvent/
112 Evaporation Method
113 The preparation of OCL3 polymeric micelles was shown
114 in Fig. 1a. Briefly, 50 ml of 50 mg/ml OCL3 stock solution in
115 chloroform was mixed with 5 ml of water and the mixture
116 was stirred vigorously at room temperature for 1 h. Chloro-
117 form was completely removed by evaporation at 4-C for
118 overnight to obtain the final solution containing OCL3
119 worm-like micelles. Solutions at other concentrations were
120 made by varying the volume of OCL3 stock solution mixed
121 with water. OCL3 spherical micelles were obtained by
122 sonicating the worm-like micelles using Fisher 60 Sonic
123 Dismembrator equipped with Fisher Ultrasonic Converter
124 (Fisher Scientific) for 25 pulses at 1 s/pulse. All solutions
125 containing OCL3 polymeric micelles were stored at 4-C to
126 minimize degradation.
127 Fluorescence Microscopy and Micelle Morphology Studies
128 PKH26, which is a rhodamine-based hydrophobic fluores-
129 cent dye, was added to OCL3 micelle solutions at about 1 ml/1 mg
130 polymer and vortexed for 10 s. The dye rapidly distributed into
131 the hydrophobic core of the micelles so the morphology of
132 micelles was visualized. Olympus IX71 inverted fluorescence
133 microscope equipped with a 60 objective lens and a Cascade
134 CCD camera was used to observe the micelles. About 25
135 images were taken for each sample tested and the contour
136 length of worm-like micelles was measured using Image-Pro
137 Plus (MediaCybernetics, Silver Spring, MD).
138 Dynamic Light Scattering
139 The average hydrodynamic micelle sizes and size distribution
140 were analyzed by dynamic light scattering (DLS) using Protein
141 Solutionsi Temperature Controlled MicroSampler and Protein
142 Solutions Dynaproi Titan (Wyatt Technologies, Santa Barbara,
143 CA) at 25-C. The laser wavelength was 782.4 nm and the
144 scattering angle was 90-. Each sample was measured in triplicate.
145 Crystallinity Analysis
146 Polycaprolactone is a highly crystalline polymer in bulk.
147 In an attempt to look for crystallization at nano-scale, an
148 alternate protocol was developed that could exploit the
149melting and annealing of the PCL core. Thus a 10 mg/ml stock
150solution of OCL3 was prepared in chloroform and 15–20 ml of
151this stock was added to 1 ml water in a glass vial. The vial was
152closed, briefly vortexed, and allowed to stand at room
153temperature for 2 h. Next, the vial was incubated at 60-C with
154the cap open, for 2 h to evaporate the chloroform in the
155solution. The vial was then allowed to incubate at 30-C for 4–6 h.
156Glycerol was added to the worms to make a 50% glycerol
157solution, which was incubated at j20-C for up to 24 h. The
158rigidity of OCL3 worms was determined by fluorescence image
159analysis as described in BFluorescence Microscopy and Micelle
160Morphology Studies.^
161The fluidity of the worm micelle core was estimated by
162measuring the fluorescence recovery after photobleaching
163(FRAP) of the PKH26 dye. Briefly, an aperture on the light
164path is used to selectively overexpose a small section of the
165worm. The fluorescence recovery in the bleached region is
166monitored by comparing the fluorescent intensity to that of
167the Intensity in an unbleached section of the worm.
168Paclitaxel (TAX) Encapsulation in OCL3 Micelles
169TAX of 50 mg/ml in methanol was added into the micelle
170solutions to obtain desired spiked TAX/polymer ratios. The
171mixture was stirred at 25-C for 20 min and transferred to dialysis
172cassettes (MWCO 10,000, Pierce, Rockford, IL). Dialysis was
173performed against DPBS (pH 7.4) for 2 h to remove methanol
174and small residues of dissolved TAX, and the obtained TAX-
175loaded micelles were separated from insoluble-free TAX aggre-
176gates by extrusion through a 10 ml thermobarrel extruder
177(Northern Lipids, Vancouver, Canada) fitted with 0.65 mm
178filtering membranes (Millipore, Bedford, MA), and further
179purified by filtration through 0.45 mm Fischerbrand MCE filter
180(Fisher Scientific). The preparation of TAX-encapsulated OCL3
181micelles is illustrated in Fig. 1a. As an alternative method, TAX
182was mixed with OCL3 polymer in chloroform solution before
183micelle formation. The TAX-loaded micelles were then
184obtained as described in BPreparation of OCL3 Polymeric
185Micelles by cosolvent/Evaporation Method^ followed by dialy-
186sis and extrusion.
187HPLC Assay Development and Validation
188A Waters HPLC system (Waters, Milford, MA) equipped
189with a 1525 Binary HPLC pump, a symmetry\ reverse-phase
190C18 5.0 mm column (4.6150 mm), and a 2487 Dual l
191absorbance UV detector was used for TAX quantification. A
192series of 1:2 TAX dilutions in acetonitrile ranging from 0 to
1930.25 mg/ml were pre-mixed with equal volume of 0.25 mg/ml
194docetaxel in acetonitrile as internal standard. The solutions
195were filtered through 0.45 mm filter followed by injection into
196HPLC system. A mobile phase of 58% H2O, 42% acetonitrile
197at a flow rate of 1 ml/min was applied. TAX was detected and
198quantified at UV 220 nm. The standard curve by plotting the
199ratio of AUC of TAX and docetaxel was established, and the
200linear range, intra-day and inter-day coefficient of variance
201(CV), lower limit of detection (LLOD), lower limit of
202quantification (LLOQ), assay accuracy and recovery (by
203testing with 3, 10, and 40 mg/ml TAX solution using the
204standard curve) were calculated. To use the validated HPLC
205assay to determine the TAX loading capacity and efficiency
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206 in OCL3 micelles, TAX-loaded micelles were pre-mixed
207 with equal volume of 0.25 mg/ml docetaxel in acetonitrile,
208 and acetonitrile in equal volume to the mixture was further
209 added, followed by the HPLC analysis using the standard
210 curve described above. TAX loading capacity and efficiency
211 were calculated based on the following expressions:
TAX loading capacity ¼ mass of TAX encapsulated in micelles=
mass of OCL3 polymeric micelles
TAX loading efficiency ¼mass of TAX encapsulated in micelles=
mass of initially added TAX
217 Thermal Analysis
218 Thermal tests of OCL3 micelles were performed by
219 differential scanning calorimetry (DSC) using a Differential
220 Scanning Calorimeter 2920 (TA instruments, New Castle, DE).
221 TAX-loaded OCL3 worm micelles were lyophilized
222 before the analysis. DSC thermograms of OCL3–TAX
223 mixture (either in bulk before TAX loading or in lyophilized
224 form after TAX loading) and OCL3 alone were then
225 obtained by heating in sealed standard aluminum pans (TA
226 instruments) from 25 to 100-C at a rate of 10-C/min followed
227 by air cool and reheating to 100-C at the same rate.
228 Micelle Stability and Paclitaxel Release Studies
229 Both worm-like and spherical micelles (10 mg/ml), either
230 drug-loaded or free, were stored at 4-C for 1 month or
231 subjected to one-time freeze–thawing cycle. Then, the
232 particle size was measured by DLS and the morphology was
233 tested by fluorescent microscopy. TAX-loaded micelles were
234 also examined for drug leakage potentially caused by storage
235 or freeze–thawing cycles by centrifugation at 3,000 rpm for 5
236 min to precipitate the TAX that may have diffused out. The
237 supernatant was then mixed with acetonitrile and internal
238 standard docetaxel for HPLC analysis.
239 Further, a dialysis method was employed to evaluate the
240 in vitro release of TAX from OCL3 micelles. TAX-loaded
241 worm-like and spherical micelles at a TAX concentration of
242 40 mg/ml were added to the dialysis cassettes and dialyzed at
243 37-C against DPBS of pH 6.8 and pH 7.4. At certain time
244 points, the release medium was sampled and fresh DPBS was
245 added to maintain the volume. The sampled medium was
246 lyophilized and redissolved in chloroform. The insoluble
247 buffer salt was removed by filtration. Chloroform was
248 evaporated then and the remaining sample was re-dissolved
249 in acetonitrile and subjected to aforementioned HPLC
250 analysis.
251 Cytotoxicity Assay
252 TAX-loaded and drug-free micelles at serial dilutions were
253 prepared per above. For comparison, 12 mg/ml TAX in ethanol
254 was mixed with equal volume of Cremophor\ EL followed by
255 sonication for 30 min. The obtained Cremophor EL TAX was
256 diluted with DPBS to obtain desired TAX concentrations.
257 Human lung-derived carcinoma cells A549 were grown
258 in F12 Ham media supplemented with 10% fetal bovine
259 serum and 100 U/ml penicillin and 100 mg/ml streptamycin at
26037-C, 5% CO2 to 60–70% confluence. A549 cells (50,000 cell/ml)
261were seeded in 96-well plates at 5,000 cells per well and
262cultured for 24 h to allow attachment. The medium was then
263exchanged and 100 ml of different tested formulations (free
264worm-like and spherical OCL3 micelles, Cremophor EL, free
265drug, TAX-loaded worm-like and spherical micelles, and
266Cremophor EL TAX) was added. As control, 100 ml of DPBS
267was added to cells not exposed to those formulations. After
26837-C, 5% CO2 incubation for 72 h, the media were discarded,
269and 100 ml/well F12 Ham medium and 11 ml/well of 5 mg/ml
270MTT solution in DPBS was added. The plates were incu-
271bated at 37-C for 3 h and the media were removed again. The
272intracellular metabolized product MTT formazan was re-
273trieved by addition of 100 ml/well DMSO and incubation at
274room temperature for 5 min. The plates were read at 550 nm,
275and the cell viability was calculated as (reading of wells with
276cells exposed to tested formulations—reading of blank wells)/
277(reading of wells with cells exposed to DPBS—reading of
278blank wells).
279Data Analysis
280All data that require non-linear regression analysis were
281processed using GraphPad Prism (Version 4.03, GraphPad
282Software, San Diego, CA). The contour length distribution of
283OCL3 worm-like micelles was fit by Gaussian distribution,
284TAX and the carrier cytotoxicity assay on A549 cells was fit
285by sigmoid dose–response curve equation.
Dave = 54.8 cm/s
2
Leff = 152 nm
Dave = 95.6 cm/s
2
deff = 57 nm
Fig. 2. Size and diffusion analysis of OCL3 micelles. The average
diffusion coefficient distribution, and the calculated effective hydro-
dynamic size (diameter or length) of worm-like (before sonication)
and spherical (after sonication) micelles were measured by DLS. The
calculation of effective length of worm-like micelles is based on
Stokes–Einstein equation: D=kT/(2phLeff) for worms (43) and
D=kT/(3phdeff) for spheres, where D is the diffusion coefficient, k
is the Boltzmann constant (1.38 10j23 J/K), T is the temperature
(25-C), h is the viscosity of the solution (1.02 mPaIs from DLS), and
deff is the hydrodynamic radius multiplied by 2
Cai et al.
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286RESULTS
287OCL3 Filomicelles are Fluid and can Fission to Spheres
288A simple physicochemical measure of aggregate stability
289for strongly segregating amphiphiles is the critical micelle
290concentration (CMC), which is expected to be exponential in
291the length of the hydrophobic block (36). Based on a CMC of
2921.2 mg/ml for a sphere-forming OCL copolymer, EO44-CL21
293(37), we estimate an immeasurably small CMC for our OCL3
294copolymer EO110-CL58 of less than 1 fg/ml (i.e. CMCOCL3 õ
295[1.2 mg/ml]58/21). For later comparison, Cremophor EL
296reportedly has a CMCCremEL õ90 mg/ml. For OCL3, micellar
297assemblies are clearly the predominant form in any aqueous
298solution. Moreover, since molecular exchange rates between
299micelles scale inversely with CMC, these low-CMC micelles can
300be considered kinetically trapped or frozen—without implying
301glassiness or crystallinity. OCL3_s weight fraction of õ0.43 for
302the hydrophilic PEO block drives assembly of most of the
303copolymer into worm-like and flexible filomicelles as observed
304by fluorescence microscopy after adding hydrophobic
305fluorescent dyes (Fig. 1b, inset). The average contour length
306of spontaneously assembled OCL3 filomicelles was calculated
307from measurement of at least 50 filomicelles, and as shown in
308Fig. 1b, most of the filomicelles are 6–7 mm, with some
309filomicelles as long as 14 mm.
310Extrusion of worm-like filomicelles at high pressures and
311flow rates through nanoporous filters has been used to
312controllably reduce their length (13), but in order to convert
313to spherical micelles—simply and quantitatively—we ex-
314posed the filomicelles to robust sonication for several
315minutes. Diffusion coefficients (Dave) were then measured
316by dynamic light scattering (DLS), and after sonication the
317effective hydrodynamic diameter was õ57 nm (Fig. 2). This is
318similar to previous õ60 nm estimates for the OCL3
319filomicelle diameter of core plus corona as based on cryo-
320TEM (13). Prior to sonication, the measured Dave proves
321significantly smaller and yields only a crude approximation
322for a larger effective size, but more important is the minimal
323overlap of the two distributions for Dave. The 22% overlap
324suggests that a small fraction at most of the pre-sonicated
a
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RFig. 3. Thermal and crystallinity analysis of OCL3 micelles. a Fluo-
rescence recovery after photobleaching (FRAP) curve on OCL3
worms: A manual aperture in the light path was used to
overexpose a small end section of the worm. The intensity in
the bleached section was compared to that of a similar length of
the worm in the unbleached section to normalize for bleaching
during imaging. The FRAP data were fitted to an exponential
recovery curve: Recovery % ¼ A 1  et=  (where A is the
maximum recovery percentage and t is the time for recovery) to
obtain an average recovery time constant t õ28 s. The 1-D
diffusivity of the PKH26 dye was calculated from D ¼ Lb2

2t
where Lb is the length of the bleached region, and t is the recovery
time constant. D õ0.9 mm2/s. b Percentage of rigid OCL3 worm-like
micelles with possible crystallized cores over 12 h incubation at
j20-C either in a 50% glycerol solution or pure water, after
heating to 60-C and cooling to 30-C. The inset figures show frames
in several different time points from sample rigid worms that were
formed in glycerol. Scale bar 5 mm. c DSC thermogram ranging
from 25 to 80-C of OCL3 polymer alone and TAX–OCL3 mixture
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325sample consists of spherical micelles. Worm-like filomicelles
326therefore predominate in freshly prepared OCL3 samples.
327In bulk, PCL is a crystalline polymer at room temper-
328ature with melting in the range of 40–60-C (38), but past
329studies of PEO-based diblock copolymers in bulk suggest
330that PEO crystallization dominates in the same temperature
331range and frustrates crystallization of the connected block
332(38). For example, the diblock PEO-polyethylene (PE) in
333bulk is 70% PEO and only 10% crystalline (PE). On the
334other hand, dilution of filomicelles into water will generally
335hydrate and dissolve any crystallinity in the PEO corona. We
336had previously reported that OCL filomicelles appear as
337flexible as worm-like micelles made from non-crystalline and
338non-glassy diblock copolymers (e.g. PEO-polybutadiene),
339which implies a fluid core of PCL (30,39). However, our
340interest in loading and storage here involved freezing for an
341extended time, which are conditions that favor crystallization.
342A very small fraction of the OCL3 filomicelles are
343inflexible coils as identified by end-to-end fluctuation<5% of
344the average end-to-end distances relative to the more fluid-
345like and flexible filomicelles (Fig. 3a). Freezing in glycerol
346gave up to 10% of the bent but crystalline-behaving worm-
347like micelles (Fig. 3a). The core fluidity of the dominant
348population of flexible filomicelles was subsequently estimat-
349ed by fluorescence recovery after photobleaching (FRAP)
350studies of immobilized filomicelles (Fig. 3b). The average
351recovery time for four different worms was õ30 s, which is
352similar to that observed in PBD cores of worm-like micelles
353with a similar molecular weight (40). The fast recovery rate in
354FRAP and the minor percentage of rigid worm micelles
355indicate a highly fluid PCL core, which would tend to favor
356loading and retention of hydrophobic drugs such as paclitaxel
357(TAX). Fluidity also provides a basis for filomicelle flexibility,
358which might allow these long micelles to reptate into diseased
359tissues, including tumors, despite their micron-scale length.
360Before examining TAX loading of filomicelles and
361spheres in dilute solution, we examined the bulk melting of
362OCL3 with or without TAX using differential scanning
363calorimetry (DSC). A melting onset temperature near 51-C
364(Fig. 3c) is consistent with PEO and/or PCL crystallization,
365and the finding that TAX exerted no significant effect on
366melting temperature indicates a relative absence of disruptive
367interactions between the drug and the copolymer. Assuming
368the melting is attributable predominantly to PEO crystalli-
369zation, as cited above (41), we estimate PEO crystallinity of
37081% from the measured endotherm peak area (106.3 J/g
371without TAX), the heat of fusion for pure PEO (õ300 J/g)
372(41), and the fEO of OCL3. With the presence of TAX, there
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UV spectrum of docetaxel (as internal standard) and paclitaxel
(TAX). b TAX loading capacity (upper panel, defined as mg TAX
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at different conditions: Total added TAX:OCL3 micelle (w/w) was
fixed at 1:5 while OCL3 concentration varied when added TAX
concentration e2 mg/ml, and OCL3 micelle concentration was fixed
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373 is no apparent decrease of crystalline PEO (79%) in bulk
374 OCL3 (102.4 J/g with TAX), suggesting that TAX interaction
375 with the copolymer is negligible.
376 Paclitaxel Integration into OCL3 Spheres and Filaments
377 TAX was then loaded into dilute micelles, and HPLC
378 analysis was used to characterize the loading properties. An
379 internal standard, docetaxel, was added in fixed amount to
380 minimize variability (Fig. 4a; Table I). The lower limit of
381 detection (LLOD) and lower limit of quantification (LLOQ)
382 were as low as 0.5 and 1 mg/ml, and both the intra-day and
383 inter-day coefficients of variance (CV) were less than 15%.
384 An accuracy of 100.2 T 7.8% (n=6) and a recovery of
385 101.7 T 6.1% (n=6), were also obtained.
386 Loading of TAX before or after micelle formation
387 showed no significant difference in capacity or efficiency
388 (not shown). Figure 4b shows the TAX loading capacity and
389 final concentration when TAX was initially added in a fixed
390 1:5 w/w ratio to micelles. Increasing TAX from 0.2 to 2 mg/ml
391 (OCL3 1–10 mg/ml) increased both the loading capacity of
392 TAX and the final solubilized TAX. Compared to spheres,
393 OCL3 filomicelles showed about 2-fold greater loading
394 capacity and at all concentrations (Fig. 4c).
395 Up to 10% w/v polymer concentration, with TAX varied
396 from 2.5 to 5 mg/ml, the loading capacity for TAX increased,
397 although the w/w loading was higher for 5% polymer.
398 Further increases of added TAX up to 20 mg/ml led to a
399 decrease in TAX solubilization regardless of morphology;
400 this is probably due to the well-known aggregation of TAX
401 at extremely high concentrations. The highest TAX solubi-
402 lization obtained in the studies of filomicelles to date was
403 3 mg/ml, which is about 10,000-fold higher than natural
404 TAX solubility in aqueous buffer [0.3 mg/ml, (18)]. Drug
405 loading efficiency defined as (loaded drug/added drug) is
406tabulated in Q2Tables II, III, and IV and consistently appears
4072-fold higher with filomicelles than with spherical micelles.
408In addition to the encapsulation capacity studies, an
409identical DSC thermogram for lyophilized OCL3–TAX mix-
410ture after encapsulation (not shown) with that of OCL3–TAX
411mixture in bulk (Fig. 3c) again verifies the unchanged melting
412temperature and the fusion heat of OCL3 copolymer. This
413further demonstrates the absence of interactions of TAX
414with its excipient during the encapsulation process.
415Stability and In Vitro Release
416Possible effects of storage, drug loading and extrusion on
417morphological changes of filomicelles were examined by
418DLS and fluorescence imaging. Fig. 5a shows that (1) both
419shapes of micelle are morphologically stable in 4-C storage
420for up to 1 month; (2) TAX integration does not affect
421micelle size, which is probably because the small loaded mass
422of TAX cannot swell the relatively large cores within
423micelles; (3) spherical micelles made by sonicating worm-like
424filomicelles show no further size change after extrusion
425whereas filomicelles become smaller. The latter result was
426confirmed by contour length measurement under fluores-
427cence microscopy (Fig. 1b), which shows that extrusion left-
428shifts and narrows the length distribution from 6.6–7.3 mm
429(95%) to 5.6–6.1 mm.
430Stability of TAX loading within OCL3 micelles was
431evaluated after 1 month of storage. Fig. 5b shows that when
432TAX-loaded micelles of either morphology were either
433maintained in fluid form at 4-C or else frozen (and perhaps
434crystalline) at j20-C, no significant leakage or precipitation
435of TAX could be detected. As emphasized above and further
436below, the filomicelle carriers are clearly stable under harsh
437treatments. For application, freezing has the advantage in
438slowing hydrolytic degradation of PCL (30).
439In addition, filomicelles were subjected to freeze–thaw
440cycles (j20-C) as another potentially disruptive operation
t1.1 Table I. Validation of HPLC-UV Assay for Palictaxel, Using
Docetaxel as the Internal Standard
Valuest1.2
Linear range 0.5–125 mg/mlt1.3
Intra-day CV <15%, max 12.3%t1.4
Inter-day CV <15%, max 14.4%t1.5
Baseline noise õ0.0001 AUt1.6
LLOD 0.5 mg/mlt1.7
LLOQ 1.0 mg/mlt1.8
Accuracy 100.2T7.8%t1.9
Recovery 101.7T6.1%t1.10
t3.1Table III. Loading Efficiency of TAX into OCL3 Spherical and
Worm-like Micelles at 10% (w/v) Fixed OCL3 Micelle Concentration
Total TAX Concentration (mg/ml) t3.2
2.5 5 10 20 t3.3
Spheres 0.34 0.30 0.09 0.03 t3.4
Worms 0.64 0.59 0.18 0.06 t3.5
t3.6Loading Efficiency mass of solubilized TAX/mass of initially added
TAX
t2.1 Table II. Loading Efficiency of TAX into OCL3 Spherical and Worm-
like Micelles When Initial Added TAX:OCL3 Micelle (w/w)=1:5
Total TAX Concentration (mg/ml)t2.2
0.2 0.4 1 2 20t2.3
Spheres 0.11 0.14 0.22 0.26 0.03t2.4
Worms 0.23 0.25 0.47 0.56 0.06t2.5
t2.6 Loading Efficiency mass of solubilized TAX/mass of initially added
TAX
t4.1Table IV. Loading Efficiency of TAX into Worm-Like OCL3
Micelles at 5 and 10% (w/v)
Total TAX Concentration (mg/ml) t4.2
2.5 5 10 t4.3
5% Worm 0.44 0.49 0.17 t4.4
10% Worm 0.64 0.59 0.18 t4.5
t4.6Loading Efficiency mass of solubilized TAX/mass of initially added
TAX
Q2
Q2 Q2
Q1
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441 relevant to storage. After a single cycle, there was no
442 significant change in the length distribution shown in Fig. 1b
443 or in TAX retention (Fig. 5c). However, the latter plot shows
444that multiple freeze–thaw cycles lead to drug leakage from
445both morphologies. TAX-loaded OCL3 micelles were frozen
446at day 0, then thawed at day 3 for the test and re-frozen,
447which was repeated at day 7, 14, 28. By the fourth cycle, the
448TAX retained in the micelle cores decreased to about 70% of
449initial loading. The reasons are not yet as clear as the
450practical implications.
451Release in vitro at 37-C was also studied at pH 7.4, per
452normal tissue pH, and also at pH 6.8 to mimic the slightly acidic
453cancerous tissue environment (29,35). As the PCL in OCL3 is
454known to undergo accelerated hydrolysis at acidic pH (30),
455TAX release rates proved to be 40% faster at lower pH but
456similar for both morphologies. This indicates that pH rather
457than shape is the more critical parameter to control drug release.
458Enhanced Cytotoxicity of TAX Released from OCL3
459Micelles
460Human lung carcinoma-derived A549 cells were used in
461cytotoxicity assays of both micelles as empty carriers and also
462as TAX-loaded carriers. The in-clinic, commercial TAX
463formulation with Cremophor EL was also included as a
464benchmark. Excipient toxicity is critically important to
465assessing the specific anticancer effect of TAX, and so for
466ease of comparison we therefore calculate the equivalent
467TAX concentration; for example, 0.8 mg TAX corresponds
468to about 1 g Cremophor EL (see BMATERIALS AND
469METHODS^). Based on such analyses, Cremophor EL
470shows a significant cytotoxic effect at only 2–3 mg/ml
471equivalents of TAX (Fig. 6a). In contrast, the OCL3
472polymeric micelles showed no obvious toxicity up to almost
473100 mg/ml TAX equivalents. Identifying the dose of exci-
474pients at which 80% of cells are still alive (Finhibition
475constant_ IC80) as a parameterization of toxicity and then
476converting to cytotoxic carrier doses yields IC80CremEL=120
477mg/ml for Cremophor EL, which appears only slightly higher
478than CMCCremEL$90 mg/ml and implies the aggregate form
479of Cremophor EL is toxic (Fig. 6b). For both filomicelles and
480spheres, IC80OCL3-micelle=1,500 mg/ml, which is about 13-
481orders of magnitude higher than CMCOCL3 and suggests
482mechanisms of cell death such as micellar poration previously
483discussed for PEO-PCL polymersomes (30). Regardless, the
48413-fold difference indicates, of course, that OCL3 polymeric
485micelles are much safer excipients.
486TAX formulations with the various carriers consistently
487improve cytotoxicity relative to delivery of free drug. While
488Fig. 6c shows that TAX-loaded Cremophor EL begins killing
489cells in the nanogram/milliliter range of TAX and kills nearly
490all cells at [TAX];10–100 mg/ml (Fig. 6a), the Cremophor EL
491excipient rather than TAX is clearly responsible for a
492significant fraction of the cytotoxicity. On the other hand,
493TAX-loaded OCL3 micelles exhibit similar cytotoxicity in
494the 10 ng/ml range, killing more than 35% A549 cancer cells.
495Importantly, the anticancer effects of TAX-loaded OCL3
496micelles throughout the tested concentrations were all
497attributed to the drug activity, instead of the toxicity from
498the carriers. The fitted sigmoid dose–response curve showed
499that the IC50-cytotoxicity of TAX-loaded OCL3 micelles (at
500õ25 nM) was 13-fold more potent than free TAX (321 nM
501for A549 cells) and also 5-fold better than Cremophor EL
502TAX (Fig. 6d). Both worm-like filomicelles and spherical
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extrusion, TAX loading and 1 month storage on the micelle effective
size, determined by DLS; b effect of 1 month storage at 4 and j20-C
on TAX leakage from micelles; c effect of multiple freeze–thawing
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503 micelles showed the same enhanced cytotoxicity. Since OCL3
504 filomicelles have a higher drug loading capacity compared to
505 spherical micelles and otherwise display similar stability and
506 efficacy as spherical micelles, the filomicelles seem an attractive
507 alternative for the emerging tests of parenteral delivery (13).
508 DISCUSSION
509 TAX is a widely used chemotherapeutic for cancer
510 treatment, but its poor water solubility [0.3 mg/ml at 25-C
511 (18)] requires clinical use of solubilizers. Cremophor EL is
512 widely used but has side-effects and limitations that are clear
513 both in these simple studies and in the clinic. PEO-based
514 spherical micelles made from amphiphilic diblock copoly-
515 mers have been explored as an alternative type of carrier
516 system to load hydrophobic drugs and dyes into the
517 hydrophobic cores, and our recent studies have focused in
518 some detail on assembly and properties of worm-like
519 filomicelles (30–34). The needed copolymers are typically
520 composed of õ0.4–0.5 weight fraction of hydrophilic PEO
521 polymer and yield flexible but highly stable filamentous
522micelles that surprisingly increase the circulation time in the
523blood stream relative to spheres. Here we showed the
524filomicelles -generally have a fluid core (Fig. 3), which favors
525integration of drugs into their hydrophobic cores, and we
526then examined the drug loading capacity and various other
527performance aspects of PEO-PCL worm-like filomicelles for
528comparison to spheres generated from the same filomicelles
529by sonication. Loading advantages are clear (Fig. 4b,c,
530Tables II, III, and IV), and some insight is gained from
531simple calculations of volume to surface area for spheres and
532cylinders. For spheres of radius r, volume=surface area ¼
5334=3 r3
 
4r2
  ¼ r=3 , whereas for cylinders of length L,
534volume=surface area ¼ r2L  2rLð Þ ¼ r=2 . If micellar
535area is thus held constant for a given mass of copolymer in
536solution, then the filomicelles are expected to carry more
537hydrophobic drug than spheres by a ratio of r=2  r=3ð Þ=
538r=3ð Þ ¼ 50% . The bigger difference of õ100% found here
539certainly highlights the advantageous loading of drugs into
540filomicelles. Furthermore, the maximum concentration of
541solubilized TAX reached 3 mg/ml, placing filomicelles just
542below Cremophor EL (marketed as formulations containing
5436 mg/ml TAX) but among the top micelle-based TAX
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Fig. 6. Cytotoxicity study and IC50 evaluation of TAX-loaded micelles on A549 human lung carcinoma celles. a Cytotoxicity of
excipient only (OCL3 spheres, worms, and Cremophor EL) on A549 cells; b comparison of the excipient concentration at which 20% cells
were killed (IC80); c cytotoxicity of different TAX formulations on A549 cells; d comparison of IC50 of different TAX formulations.
Sigmoid doseresponsive equation : Y ¼ Bottom þ Top  Bottomð Þ= 1 þ 10^ LogIC50  Xð Þ  HillSlopeð Þð Þ, where X is the logarithm
of TAX concentration, Y is the response and starts at bottom and goes to top, and HillSlope is the slope for the linear dropping region in
the sigmoid curve
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544 delivery systems that usually enhance TAX solubility to 1–2
545 mg/ml (18,21,23–25,42).
546 Although filomicelles appear novel and were perhaps
547 even overlooked in past formulations that relied on sonica-
548 tion, PEO-PCL block copolymer has been widely explored
549 for drug delivery applications in the past. It consists of FDA-
550 approved PEO plus the approved and degradable polyester
551 PCL. We have previously found that hydrolytic degradation
552 of PCL predominates at the distal hydroxyl-end such that the
553 hydrophobic mass of PCL gradually decreases, increasing the
554 weight fraction of PEO and converting the worm-like
555 micelles towards spherical micelles (30). This process is
556 greatly accelerated by low pH, which also accelerates release
557 of TAX. On the other hand, degradation of PCL is
558 significantly limited at low temperatures of 4 and j20-C,
559 and the results here demonstrate stable storage of OCL3
560 filomicelle morphologies at these low temperatures for a
561 month (Fig. 5) without major complications from crystalliza-
562 tion (Fig. 3). While multiple freeze–thaw cycles leads to loss
563 of TAX for both worm-like and spherical micelles—as do
564 other harsh conditions in extrusion, sonication, and lyophili-
565 zation (not shown), only 1–2 cycles of freeze–thaw cycles
566 have no obvious effect. Care should nonetheless be taken
567 when preparing or storing TAX-loaded worm micelles.
568 Given the persistent circulation of filomicelles and
569 minimal accumulation in rat lung (21), specific targeting of
570 these novel morphologies to lung tumors should eventually
571 provide a clear indication of directed drug delivery possibil-
572 ities with filomicelles. Human lung cancer also continues to
573 account for a significant of all cancer deaths. With these
574 factors in mind as well as the intrinsic toxicity of Cremophor
575 EL (Fig. 6a,b), we examined the in vitro delivery by
576 filomicelles of TAX to A549 lung carcinoma cells, and we
577 find that the spherical micelles and filomicelles are both 13-
578 fold less toxic than Cremophor EL and, with loaded TAX,
579 about 5-fold more effective in delivering a cytotoxic dose
580 (Fig. 6c,d). Furthermore, since delivery of Cremophor EL is
581 not pH-sensitive, such an in vivo formulation will tend to be
582 less selective for tumors and further increase the risk of the
583 excipient toxicity to normal cells.
584 CONCLUSION
585 Taken together, OCL3 based filomicelles appear to
586 provide an excellent system for delivery of hydrophobic
587 drugs, with enhanced drug solubility compared to spherical
588 micelles but similar efficacy for a given dose of TAX.
589 Morphological changes thus did not adversely impact drug
590 release behavior and in vitro bioactivity. Future studies are
591 likely to include conjugation with targeting moieties towards
592 lung cancer cells and studies of in vivo tumor models with
593 parenteral administration. Morphological effects under these
594 more pathophysiological conditions clearly need to be
595 mapped out.
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